Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

Beta-3 Adrenergic Receptor Agonists Cause an Increase in Gastrointestinal Transit Time in Wild-type Mice, But Not in Mice Lacking the Beta-3 Adrenergic Receptor

Daniel S. Fletcher, Mari Rios Candelore, Danica Grujic, Bradford B. Lowell, Silvi Luell, Vedrana S. Susulic and D. Euan Macintyre
Journal of Pharmacology and Experimental Therapeutics November 1998, 287 (2) 720-724;
Daniel S. Fletcher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mari Rios Candelore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Danica Grujic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradford B. Lowell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvi Luell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vedrana S. Susulic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Euan Macintyre
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The effects of beta-3 adrenergic receptor (β3-AR) agonists on gastrointestinal (GI) motility, as reported by stomach retention and intestinal transit of radiolabelled charcoal, were compared in wild-type (WT) mice and in transgenic mice lacking β3-AR (β3-AR[KO]) or having β3-AR in white and brown adipose tissue only (β3-AR[WAT+BAT]). After s.c. administration of 3 mg/kg of the selective, rodent specific β3-AR agonists BRL 35135, CL 316,243 or ICI 198,157, WT mice exhibited a significant decrease in the extent of movement of radiotracer through the stomach and intestines, indicative of decreased GI motility. These compounds also caused an increase in plasma glycerol levels in the WT mice, suggesting that increased lipolysis in adipose tissue had been evoked. None of these compounds had an effect on GI motility or evoked lipolysis in the β3-AR[KO] mice. Treatment of WT mice with SR 56811A, a β3-AR agonist that exhibited a relatively lower affinity for rodent β3-AR in vitro, did not affect GI motility or plasma glycerol levels in WT or β3[KO] mice when administered s.c. at 3 mg/kg. Clonidine, an alpha-2 adrenergic receptor agonist, used as a positive control in these GI studies, caused a decrease in GI motility in both WT and β3-AR[KO] mice. These results are consistent with a postulated role for β3-AR in regulation of GI motility in the mouse. However, treatment of β3-AR[WAT+BAT] mice with 3 mg/kg BRL 35135 resulted in elevated plasma glycerol levels, as well as increased stomach retention and decreased intestinal transit of radiotracer. These results suggest that this β3-AR agonist may exert its effects on the GI tract indirectly, through an unknown signaling mechanism activated by agonism of β3-AR in adipose tissue.

Footnotes

  • Send reprint requests to: Dr. Daniel S. Fletcher, R80Y-150, Merck & Co., P.O. Box 2000, Rahway, NJ 07065.

  • ↵1 Current address: Division of Endocrinology, Department of Medicine, Harvard Medical School, Boston, MA 02215.

  • ↵2 Current address: Wyeth-Ayerst Research, Princeton, NJ 08543.

  • Abbreviations:
    β3-AR
    beta-3 adrenergic receptor
    GI
    gastrointestinal
    WT
    wild-type mouse
    β3-AR[KO]
    transgenic mice lacking β3-AR
    β3-AR[WAT+BAT]
    transgenic mice lacking β3-AR in all tissues except white and brown adipose tissue, GC, geometric center
    • Received March 11, 1998.
    • Accepted June 12, 1998.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 287, Issue 2
1 Nov 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Beta-3 Adrenergic Receptor Agonists Cause an Increase in Gastrointestinal Transit Time in Wild-type Mice, But Not in Mice Lacking the Beta-3 Adrenergic Receptor
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Beta-3 Adrenergic Receptor Agonists Cause an Increase in Gastrointestinal Transit Time in Wild-type Mice, But Not in Mice Lacking the Beta-3 Adrenergic Receptor

Daniel S. Fletcher, Mari Rios Candelore, Danica Grujic, Bradford B. Lowell, Silvi Luell, Vedrana S. Susulic and D. Euan Macintyre
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 720-724;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Beta-3 Adrenergic Receptor Agonists Cause an Increase in Gastrointestinal Transit Time in Wild-type Mice, But Not in Mice Lacking the Beta-3 Adrenergic Receptor

Daniel S. Fletcher, Mari Rios Candelore, Danica Grujic, Bradford B. Lowell, Silvi Luell, Vedrana S. Susulic and D. Euan Macintyre
Journal of Pharmacology and Experimental Therapeutics November 1, 1998, 287 (2) 720-724;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Effects of Antidepressants and Benzodiazepine-Type Anxiolytic Agents on Hepatic Porphyrin Accumulation in Primary Cultures of Chick Embryo Liver Cells
  • Interaction of Diclofenac and Quinidine in Monkeys: Stimulation of Diclofenac Metabolism
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics